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Supplementary Table 1.  Comparison of Biomarkers of Renal Function During Follow-Up According to Development of 
End-Stage Renal Disease 
Comparison of Biomarkers in those that develop ESRD vs. Not 
 Time Prior to ESRD/Modified End of Follow-up P-values 
Biomarker 3 years 2 years 1 year Time of 
ESRD/mEnd 
of Follow-up 
Estimated 
Time of 
Divergencea 
Equality Interaction 
 Placebo Group    
 ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
   
Creatinine (mg/dL)b 2.0 vs 1.7; 
p<0.001 
2.4 vs 1.8; 
p<0.001 
2.8 vs 1.9; 
p<0.001 
4.3 vs 1.9; 
p<0.001 
>3 years <0.001 <0.001 
eGFR (mL/min/1.73m2) 33.5 vs 38.2; 
p<0.001 
28.1 vs 36.7; 
p<0.001 
23.3 vs 35.4; 
p<0.001 
15.6 vs 34.9; 
p<0.001 
>3 years <0.001 <0.001 
Urine Protein/Creatinine Ratiob 1.4 vs 0.4; 
p<0.001 
1.7 vs 0.4; 
p<0.001 
2.1 vs 0.4; 
p<0.001 
2.5 vs 0.5; 
p<0.001 
>3 years <0.001 <0.001 
 Darbepoetin Group    
 ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
   
Creatinine (mg/dL)b 2.0 vs 1.7; 
p<0.001 
2.3 vs 1.8; 
p<0.001 
2.7 vs 1.8; 
p<0.001 
4.6 vs 1.9; 
p<0.001 
>3 years <0.001 <0.001 
eGFR (mL/min/1.73m2) 32.5 vs 38.2; 
p<0.001 
28.6 vs 37.7; 
p<0.001 
24.1 vs 37.0; 
p<0.001 
14.7 vs 35.9; 
p<0.001 
>3 years <0.001 <0.001 
Urine Protein/Creatinine Ratiob 1.7 vs 0.4; 
p<0.001 
2.1 vs 0.4; 
p<0.001 
2.7 vs 0.4; 
p<0.001 
3.1 vs 0.5; 
p<0.001 
>3 years <0.001 <0.001 
P for Equality tests the null hypothesis that the curves are superimposable; P for Interaction tests the null hypothesis that the curves are parallel.  
a Estimated time of divergence of biomarkers of interest (developed ESRD vs. not) was defined as the latest time at which the difference in point 
estimates became significant at α=0.01.   
b Groups are summarized and compared using geometric means 
eGFR, estimated glomerular filtration rate 
 
Supplementary Table 2.  Comparison of Biomarkers During Follow-Up According to Development of End-Stage Renal 
Disease Using a Refined Non-ESRD Comparator Group 
 
Comparison of Biomarkers in those who develop ESRD (n=668) vs. Propensity Score Matched Sample of 
Non-ESRD (n=670) 
 Time Prior to ESRD/Modified End of Follow-up P-values 
Biomarker 3 years 2 years 1 year Time of 
ESRD/mEnd of 
Follow-up 
Equality Interaction 
 Placebo Group   
 ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
  
Hemoglobin (g/dL) 10.4 vs 10.1; 
p<0.001 
10.3 vs 10.2; 
p=0.36 
10.2 vs 10.4; 
p=0.005 
9.5 vs 10.4; 
p<0.001 
<0.001 <0.001 
Darbepoetin  
(Mean Dose in mcg/month) 
1.3 vs 6.0; 
p=0.009 
3.2 vs 5.9; 
p=0.037 
7.4 vs 6.7; 
p=0.54 
18.5 vs 8.0; 
p<0.001 
<0.001 <0.001 
Darbepoetin Dose Difference 
([ESRD – non-ESRD] in mcg/month) -4.8 -2.7 +0.7 +10.5 
<0.001 <0.001 
Ferritin (mcg/L)b 147 vs 144; 
p=0.81 
148 vs 143; 
p=0.52 
172 vs 151; 
p=0.047 
204 vs 169; 
p=0.013 
0.002 0.004 
Transferrin Saturation (%) 24.9 vs 25.7; 
p=0.44 
24.5 vs 25.6; 
p=0.14 
26.1 vs 25.8; 
p=0.74 
24.3 vs 26.1; 
p=0.036 
0.14 0.10 
CRP (mg/L)b, c 3.7 vs 2.7; 
p=0.030 
3.9 vs 2.9; 
p=0.001 
3.9 vs 3.4; 
p=0.057 
5.8 vs 3.3; 
p<0.001 
<0.001 0.028 
 Darbepoetin Group   
 ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
  
Hemoglobin (g/dL) 11.2 vs 11.1; 
p=0.16 
11.7 vs 11.6; 
p=0.76 
11.9 vs 11.9; 
p=0.27 
11.5 vs 12.4; 
p<0.001 
<0.001 <0.001 
Darbepoetin  
(Mean Dose in mcg/month) 
131 vs 153; 
p=0.010 
138 vs 146; 
p=0.28 
162 vs 167; 
p=0.48 
232 vs 197; 
p=<0.001 
<0.001 <0.001 
Darbepoetin Dose Difference 
([ESRD – non-ESRD] in mcg/month) -23 -8 -5 +36 <0.001 <0.001 
Ferritin (mcg/L)b 92 vs 107; 
p=0.10 
119 vs 120; 
p=0.90 
151 vs 144; 
p=0.46 
179 vs 183; 
p=0.75 
0.09 0.047 
Transferrin Saturation (%) 22.0 vs 21.6; 
p=0.73 
25.6 vs 27.2; 
p=0.12 
29.8 vs 29.4; 
p=0.62 
29.5 vs 34.0; 
p<0.001 
<0.001 <0.001 
CRP (mg/L)b, c 2.9 vs 3.7; 
p=0.08 
3.5 vs 3.4; 
p=0.80 
3.6 vs 4.0; 
p=0.22 
5.3 vs 3.7; 
p=0.002 
0.002 <0.001 
 
 
Supplementary Figure 1.  TREAT Study Darbepoetin Management Protocol 
 
 
 
Supplementary Figure 2.  TREAT Study Iron Management Protocol 
 
 
 
Supplementary Figure 3. Trajectory of Hemoglobin According to Development 
of ESRD in Subgroups of Participants With and Without Baseline ACEi/ARB Use 
 
 
 
 
 
Supplementary Figure 4. Trajectory of Serum Creatinine According to 
Development of ESRD 
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Supplementary Figure 5. Trajectory of Estimated Glomerular Filtration Rate 
According to Development of ESRD  
  
Supplementary Figure 6. Trajectory of Urine Protein/Creatinine Ratio According 
to Development of ESRD 
 
 
 
